Emerging CTLA-4 Therapy in Squamous NSCLC

In this segment, the panel examines early clinical data for a next-generation CTLA-4-directed therapy in patients with advanced squamous non-small cell lung cancer (NSCLC) whose disease has progressed following PD-L1 inhibitor and chemotherapy treatment. Dr. Christian Rolfo reviews the phase 3 study's staged design, noting that the initial stage was intended primarily to evaluate safety, determine dosing, and identify preliminary efficacy signals before the subsequent pivotal stage. The panel discusses the selection of the dose carried forward and the early observation of activity in squamous NSCLC. The first-stage randomized comparison included patients with squamous disease who received the investigational CTLA-4-directed therapy or docetaxel, providing a contemporary control arm relevant to clinical practice. Dr. Rolfo notes that overall survival was the primary endpoint and that the study population included patients with disease progression following PD-L1-directed therapy. However, the experts emphasize that the squamous NSCLC dataset remained limited in size and that the observed survival findings were nominal rather than based on a formal hypothesis test. They therefore characterize the early results as requiring confirmation in the subsequent stage of the trial.